Annual Accounts Receivable
$473.57 M
+$16.13 M+3.53%
December 31, 2024
Summary
- As of February 7, 2025, IDXX annual accounts receivable is $473.57 million, with the most recent change of +$16.13 million (+3.53%) on December 31, 2024.
- During the last 3 years, IDXX annual accounts receivable has risen by +$105.23 million (+28.57%).
- IDXX annual accounts receivable is now at all-time high.
Performance
IDXX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$473.57 M
-$37.67 M-7.37%
December 31, 2024
Summary
- As of February 7, 2025, IDXX quarterly accounts receivable is $473.57 million, with the most recent change of -$37.67 million (-7.37%) on December 31, 2024.
- Over the past year, IDXX quarterly accounts receivable has increased by +$16.13 million (+3.53%).
- IDXX quarterly accounts receivable is now -11.25% below its all-time high of $533.61 million, reached on June 30, 2024.
Performance
IDXX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
IDXX Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +3.5% | +3.5% |
3 y3 years | +28.6% | +18.2% |
5 y5 years | +75.8% | +18.2% |
IDXX Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +28.6% | -11.3% | +28.6% |
5 y | 5-year | at high | +75.8% | -11.3% | +75.8% |
alltime | all time | at high | +936.5% | -11.3% | +936.5% |
IDEXX Laboratories Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $473.57 M(+3.5%) | $473.57 M(-7.4%) |
Sep 2024 | - | $511.25 M(-4.2%) |
Jun 2024 | - | $533.61 M(+5.2%) |
Mar 2024 | - | $507.21 M(+10.9%) |
Dec 2023 | $457.44 M(+14.2%) | $457.44 M(+1.0%) |
Sep 2023 | - | $452.70 M(-2.0%) |
Jun 2023 | - | $461.86 M(+3.5%) |
Mar 2023 | - | $446.02 M(+11.3%) |
Dec 2022 | $400.62 M(+8.8%) | $400.62 M(+3.2%) |
Sep 2022 | - | $388.07 M(-6.0%) |
Jun 2022 | - | $412.90 M(+2.7%) |
Mar 2022 | - | $402.24 M(+9.2%) |
Dec 2021 | $368.35 M(+11.1%) | $368.35 M(-2.2%) |
Sep 2021 | - | $376.76 M(-1.5%) |
Jun 2021 | - | $382.31 M(+0.1%) |
Mar 2021 | - | $381.79 M(+15.2%) |
Dec 2020 | $331.43 M(+23.1%) | $331.43 M(-1.8%) |
Sep 2020 | - | $337.59 M(+5.4%) |
Jun 2020 | - | $320.32 M(+6.8%) |
Mar 2020 | - | $299.98 M(+11.4%) |
Dec 2019 | $269.31 M(+8.2%) | $269.31 M(+0.4%) |
Sep 2019 | - | $268.32 M(-6.2%) |
Jun 2019 | - | $286.15 M(+1.8%) |
Mar 2019 | - | $281.16 M(+13.0%) |
Dec 2018 | $248.85 M(+6.1%) | $248.85 M(-5.9%) |
Sep 2018 | - | $264.56 M(-0.2%) |
Jun 2018 | - | $265.01 M(+2.0%) |
Mar 2018 | - | $259.87 M(+10.8%) |
Dec 2017 | $234.60 M(+14.7%) | $234.60 M(+2.8%) |
Sep 2017 | - | $228.16 M(-5.0%) |
Jun 2017 | - | $240.26 M(+6.6%) |
Mar 2017 | - | $225.35 M(+10.2%) |
Dec 2016 | $204.49 M(+8.6%) | $204.49 M(-0.1%) |
Sep 2016 | - | $204.70 M(-3.5%) |
Jun 2016 | - | $212.23 M(+0.1%) |
Mar 2016 | - | $212.07 M(+12.6%) |
Dec 2015 | $188.32 M(+23.6%) | $188.32 M(-1.4%) |
Sep 2015 | - | $190.90 M(-4.3%) |
Jun 2015 | - | $199.44 M(+1.6%) |
Mar 2015 | - | $196.23 M(+28.8%) |
Dec 2014 | $152.38 M(-3.6%) | $152.38 M(-5.0%) |
Sep 2014 | - | $160.47 M(-4.8%) |
Jun 2014 | - | $168.64 M(-6.3%) |
Mar 2014 | - | $179.92 M(+13.8%) |
Dec 2013 | $158.04 M(+14.3%) | $158.04 M(+4.3%) |
Sep 2013 | - | $151.57 M(-4.7%) |
Jun 2013 | - | $159.12 M(+0.1%) |
Mar 2013 | - | $158.99 M(+14.9%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2012 | $138.32 M(-2.1%) | $138.32 M(-2.2%) |
Sep 2012 | - | $141.37 M(-3.9%) |
Jun 2012 | - | $147.16 M(-8.6%) |
Mar 2012 | - | $160.98 M(+13.9%) |
Dec 2011 | $141.28 M(+17.7%) | $141.28 M(+4.7%) |
Sep 2011 | - | $134.92 M(-9.6%) |
Jun 2011 | - | $149.31 M(+8.6%) |
Mar 2011 | - | $137.55 M(+14.5%) |
Dec 2010 | $120.08 M(+4.3%) | $120.08 M(-0.3%) |
Sep 2010 | - | $120.45 M(-5.3%) |
Jun 2010 | - | $127.14 M(-2.6%) |
Mar 2010 | - | $130.52 M(+13.4%) |
Dec 2009 | $115.11 M(+3.2%) | $115.11 M(-0.0%) |
Sep 2009 | - | $115.14 M(-3.1%) |
Jun 2009 | - | $118.78 M(+3.1%) |
Mar 2009 | - | $115.25 M(+3.4%) |
Dec 2008 | $111.50 M(+2.9%) | $111.50 M(-0.5%) |
Sep 2008 | - | $112.05 M(-7.1%) |
Jun 2008 | - | $120.56 M(-3.7%) |
Mar 2008 | - | $125.25 M(+15.6%) |
Dec 2007 | $108.38 M(+33.2%) | $108.38 M(+4.8%) |
Sep 2007 | - | $103.41 M(-3.1%) |
Jun 2007 | - | $106.68 M(+1.8%) |
Mar 2007 | - | $104.79 M(+28.8%) |
Dec 2006 | $81.39 M(+13.5%) | $81.39 M(+2.6%) |
Sep 2006 | - | $79.30 M(-6.1%) |
Jun 2006 | - | $84.47 M(+3.1%) |
Mar 2006 | - | $81.92 M(+14.3%) |
Dec 2005 | $71.69 M(+9.2%) | $71.69 M(+5.3%) |
Sep 2005 | - | $68.10 M(-6.9%) |
Jun 2005 | - | $73.14 M(-3.3%) |
Mar 2005 | - | $75.62 M(+15.2%) |
Dec 2004 | $65.64 M(+21.6%) | $65.64 M(+13.3%) |
Sep 2004 | - | $57.95 M(-2.3%) |
Jun 2004 | - | $59.29 M(-3.5%) |
Mar 2004 | - | $61.47 M(+13.9%) |
Dec 2003 | $53.98 M(+18.1%) | $53.98 M(+6.5%) |
Sep 2003 | - | $50.67 M(-0.2%) |
Jun 2003 | - | $50.78 M(-1.5%) |
Mar 2003 | - | $51.58 M(+12.9%) |
Dec 2002 | $45.69 M(-10.0%) | $45.69 M(-4.0%) |
Sep 2002 | - | $47.61 M(-0.8%) |
Jun 2002 | - | $48.00 M(-7.1%) |
Mar 2002 | - | $51.68 M(+1.8%) |
Dec 2001 | $50.77 M(-11.3%) | $50.77 M(-6.0%) |
Sep 2001 | - | $53.99 M(-4.4%) |
Jun 2001 | - | $56.48 M(-0.6%) |
Mar 2001 | - | $56.84 M(-0.7%) |
Dec 2000 | $57.27 M | $57.27 M |
FAQ
- What is IDEXX Laboratories annual accounts receivable?
- What is the all time high annual accounts receivable for IDEXX Laboratories?
- What is IDEXX Laboratories annual accounts receivable year-on-year change?
- What is IDEXX Laboratories quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for IDEXX Laboratories?
- What is IDEXX Laboratories quarterly accounts receivable year-on-year change?
What is IDEXX Laboratories annual accounts receivable?
The current annual accounts receivable of IDXX is $473.57 M
What is the all time high annual accounts receivable for IDEXX Laboratories?
IDEXX Laboratories all-time high annual accounts receivable is $473.57 M
What is IDEXX Laboratories annual accounts receivable year-on-year change?
Over the past year, IDXX annual accounts receivable has changed by +$16.13 M (+3.53%)
What is IDEXX Laboratories quarterly accounts receivable?
The current quarterly accounts receivable of IDXX is $473.57 M
What is the all time high quarterly accounts receivable for IDEXX Laboratories?
IDEXX Laboratories all-time high quarterly accounts receivable is $533.61 M
What is IDEXX Laboratories quarterly accounts receivable year-on-year change?
Over the past year, IDXX quarterly accounts receivable has changed by +$16.13 M (+3.53%)